Milestone Pharmaceuticals Ownership
| MIST Stock | USD 2.05 0.15 7.89% |
Shares in Circulation | First Issued 2019-03-31 | Previous Quarter 66 M | Current Value 62 M | Avarage Shares Outstanding 38.2 M | Quarterly Volatility 15.7 M |
Milestone |
Milestone Stock Ownership Analysis
About 47.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.67. Milestone Pharmaceuticals had not issued any dividends in recent years. The entity had 1-1 split on the 24th of March 2020. Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company was incorporated in 2003 and is headquartered in Montral, Canada. Milestone Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 29 people. To find out more about Milestone Pharmaceuticals contact Joseph MBA at 514 336 0444 or learn more at https://www.milestonepharma.com.Besides selling stocks to institutional investors, Milestone Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Milestone Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Milestone Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Milestone Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Milestone Pharmaceuticals Insider Trades History
Less than 1% of Milestone Pharmaceuticals are currently held by insiders. Unlike Milestone Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Milestone Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Milestone Pharmaceuticals' insider trades
Milestone Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Milestone Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Milestone Pharmaceuticals backward and forwards among themselves. Milestone Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Milestone Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | The Toronto-dominion Bank | 2024-12-31 | 750 K | Citadel Advisors Llc | 2024-12-31 | 608.2 K | Stonepine Capital Management Llc | 2024-12-31 | 500 K | Ikarian Capital, Llc | 2024-12-31 | 466 K | Boxer Capital Management, Llc | 2024-12-31 | 309 K | Boxer Capital Llc | 2024-09-30 | 309 K | Ubs Group Ag | 2024-12-31 | 89.5 K | Virtu Financial Llc | 2024-12-31 | 72 K | Envestnet Asset Management Inc | 2024-12-31 | 63.7 K | Blackrock Inc | 2024-12-31 | 4.1 M | Millennium Management Llc | 2024-12-31 | 2.7 M |
Milestone Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Milestone Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Milestone Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Milestone Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Milestone Pharmaceuticals Outstanding Bonds
Milestone Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Milestone Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Milestone bonds can be classified according to their maturity, which is the date when Milestone Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Milestone Pharmaceuticals Corporate Filings
8K | 19th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10K | 13th of March 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
F4 | 29th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Milestone Stock Analysis
When running Milestone Pharmaceuticals' price analysis, check to measure Milestone Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Milestone Pharmaceuticals is operating at the current time. Most of Milestone Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Milestone Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Milestone Pharmaceuticals' price. Additionally, you may evaluate how the addition of Milestone Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.